Trending

Psychiatry

NICE rejects J&J’s Spravato for treatment-resistant depression

NICE rejects J&J’s Spravato for treatment-resistant depression

The UK healthcare cost-effectiveness agency has said it will not recommend funding for Johnson & Johnson’s antidepressant nasal

X

NICE rejects J&J’s Spravato for treatment-resistant depression

https://pharmaphorum.com/news/nice-rejects-jjs-spravato-for-treatment-resistant-depression/

J&J seeks wider use of its Spravato antidepressant in US

J&J seeks wider use of its Spravato antidepressant in US

Johnson & Johnson has filed for US approval for a new claim on the label for its nasal

X

J&J seeks wider use of its Spravato antidepressant in US

https://pharmaphorum.com/news/jj-seeks-wider-use-of-its-spravato-antidepressant-in-us/

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

Improving targeted treatments and partnering on initiatives to reduce stigma and support mental health patients.

X

Looking back, looking forward – Janssen’s 60 years on the psychiatry horizon

https://pharmaphorum.com/views-and-analysis/janssen-mental-health-psychiatry/

CONTINUE TO SITE >

Close in 10 seconds

Pharmaphorum.com